Shopping Cart

購物車內沒有任何商品。

關於阿瑞

關於阿瑞

▍研習證照

  • 醫藥專利導讀、侵權案例解析與策略佈局 (光鹽2022)
  • AI與Big Data驅動智慧財產營運新模式 (磐安MMOT2021)
  • 生技醫藥專利培訓、醫藥專利導讀、侵權案例解析與策略佈局 (光鹽2021)
  • 新藥委外開發成功關鍵金三角評估、管理與策略規劃 (生技產業深耕學院2020)
  • 專利檢索與資訊分析 (智合創新顧問有限公司2020)
  • 遴選臨床試驗優良供應商 (光鹽2020)
  • 國際技術移轉經理人培訓 (Oxford OXENTIA2020)
  • 2020國際技術移轉培訓 (資策會2020)
  • 創業股權規劃與技術作價 (財團法人生技中心2020)
  • 製藥工程師培訓:藥廠法規人員實務 (光鹽學苑2019)
  • 跨領域科技管理研習班 (磐安MMOT2019)
  • 大健康人才培訓班 (2019)
  • 精準醫療神經疾病分子檢測 (2019)
  • 科技與智慧財產最新發展因應策略 (MMOT2019)

台大生理學研究所博士

國防醫學院生理學研究所

高雄醫學大學藥學系

2017台北國際發明展金牌

20餘項醫藥發明專利

中研院智財處 專利外審委員

百朗克醫藥公司

亞瑟瑞智科技管理顧問公司

Aristotle Research Award

科技部特殊優秀人才獎(2012~)

俄羅斯國際事務部科學基金會(RSF, RIAC) 審查委員

台中市政府南投縣政府 防毒委員

國防醫學院生理學研究所

高雄醫學大學藥學系

▍專業表現

  • 專業學術論文：超過百篇
  • 學術會議發表論文：約200篇
  • 醫藥發明專利：20餘項
  • 醫藥技術移轉：5項
  • 藥物開發：治療巴金森氏症多國多中心二期臨床試驗
    (美國FDA、TFDA同步)
  • 多本國際學術期刊審查人
  • 俄羅斯國際事務部科學基金會(RSF, RIAC) 審查委員

▍醫藥研究主題

  • 巴金森氏症、失智症、癲癇
  • Physiology, Pharmacology, Neuroscience, Neuropharmacology, Psychology, Biopsychology, Neurodegeneration, Parkinson’s disease, Dementia with Lewy bodies, Animal Study, Behavioral science, Cognitive function

▍榮譽

  • 國科會傑出人才獎(2012至今連續10年獲獎)
  • 科技部與德國學術交流總署獎學金
  • 歐洲亞里斯多德研究獎(Aristotle Research Award)
  • 中山醫學大學優良教師
  • 台中市SUPER教師
立即聯絡

醫學專利

醫學專利、「權」球布局

包含瑞典、英國、荷蘭、德國、波蘭、法國、瑞士、義大利、西班牙、土耳其、中國、韓國、日本、台灣、澳洲、加拿大與美國等

專業經驗

PROFESSIONAL EXPERIENCE
DepartmentInstitutionPositionDate
Department of Psychology 心理學系Chung Shan Medical University 中山醫學大學Professor 教授兼主任(2022/08/01)2011/08 ~ present
Russian International Affairs Council (RIAC)俄羅斯國際事務部the Review Board of the Russian Science Foundation (RSF)俄國科學基金會Reviewer2019/04 ~present
台中市政府 Taichung City GovernmentDrug Control Committee, Health Bureau毒防委員Independent Expert Consultant2017.01.01- present
台中市政府 Taichung City Government食品藥物安全處Food and Drug Safety審查委員Independent Reviewer2017.01.01- present
南投縣政府 Nantou County GovernmentDrug Control Committee, Health Bureau毒防委員Independent Expert Consultant2016.08.01- 2018.07.31
亞瑟瑞智科技管理顧問公司Arthur Wisdom Technology Consultants Co. Ltd.監察人Founding Shareholder2016.07.06~
百朗克醫藥公司BrainX Corporation發起董事Founding Shareholder2016.07.06~
The Chinese Physiological Society 中國生理學會 Member of the Council 理事2016/04/05 ~
瑞金抗齡基金會 發起董事2017.01.01 ~
The Chinese Physiological Society 中國生理學會 Executive Secretary 秘書長2012/03/01 ~ 2016/04/01
Student Affairs 學務處Chung Shan Medical University 中山醫學大學Dean 學務長2012.08.01~ 2014.07.31
中山醫學大學 Chung Shan Medical University教師會 Teacher association理事長 Director-General2012/01/01 ~ 2012/07/31
Chung Shan Medical University Hospital 中山醫院Human Subject Research Ethics Committee/ IRB 人體研究委員會Independent Expert Consultant 獨立諮詢委員2011/08/01 ~ present 
Taiwan Neuromodulation Society 台灣神經調節學會 Member of the Council 理事2007/12 ~ present
Dept. Psychopharmacology 藥理學科Central Institute of Mental Health, Germany 德國心智健康研究院Visiting Fellow 訪問學者2007/06/30 ~ 07/11
Division of Extracurricular Activities 課外活動組Office of Student Affairs, Chung Shan Medical University 中山醫學大學Chair 主任2006/03 ~ 2008/03
Department of Psychology 心理學系Chung Shan Medical University 中山醫學大學Associate Professor 副教授2005/08 ~ 2011/07/31
Department of Psychology 心理學系Chung Shan Medical University 中山醫學大學Assistant Professor 助理教授2002/08 ~ 2005/07/31
Experimental and Physiological Psychology 實驗與生理心理學系Philipps University of Marburg, Germany 德國Marburg大學Visiting Scholar 訪問學者2001/03 ~ 2002/02
Chang Gung Nursing Junior College 長庚護專 Lecturer 兼任講師2000/09 ~ 2001/01
Tri-Service General Hospital 三軍總醫院 Pharmacist 藥劑師1993/01 ~ 1993/06
Chinese Air Force 空軍 Commissioned Lieutenant 少尉軍官1990/07 ~ 1992/05

PUBLICATIONS

(A)  Referred Paper
  1. Lin CL,TL Zheng#, SH Tsou#, HM Chang#, LH Tseng, CH Yu*, CSui Hung*, YJ Ho*. Amitriptyline improves cognitive and neuronal function in a rat model that mimics dementia with lewy bodies. Behav Brain Res. 435: 114035, Aug. 11, 2022. (SCI)
  2. Wu XB, CH Lai, YJ Ho, CH Kuo, PF Lai, CY Tasi, G Jin, M Wei, B Mahalakshmi, CY Huang*, SD Lee*. Anti-apoptotic Effects of Diosgenin on Ovariectomized Hearts. Stroids 179: 108980, 2022. (SCI) IF= 2.668; Ranking: 112/146= 76.7%
  3. Chu YH, WC Liao, YJ Ho, CH Huang, TJT Tseng, CH Liu*. Targeting chondroitin sulfate reduces invasiveness of glioma cells by suppressing CD44 and integrin β1 expression. Cells 10(12): 3594, 2021. (SCI) IF=6.6; Ranking: 51/195= 26.15%
  4. Tikhonova MA*, TG Amstislavskaya, YJ Ho, AA Akopyan1, MV Tenditnik, MV Ovsyukova1, AA Bashirzade, NI Dubrovina1, LI Aftanas. Neuroprotective effects of ceftriaxone involve the reduction of Ab burden and neuroinflammatory response in a mouse model of Alzheimer’s disease. Front Neurosci, 15: 736786, 29th Sep, 2021. DOI: 10.3389/fnins.2021.736786. 2021. (SCI) IF=4.677; Ranking: 88/273= 32.23%
  5. Liu CH, WC Liao, HH Li, LH Tseng, WH Wang, H Tung, PJ Lin, HT Jao, WY Liu, CS Hung*, CL Lin*, YJ Ho*. Treatment with the combination of clavulanic acid and valproic acid led to recovery of neuronal and behavioral deficits in an epilepsy rat model. Fundamental & Clinical Pharmacology 35 (6):1032-44, 29th Sep. 2021. DOI:10.1111/fcp.12729. (SCI) IF=2.748; Ranking: 178/276=64.5%
  6. Chang CC, SH Tsou, WJ Chen, YJ Ho, HC Hung, GY Liu, SK Singh, HH Li, CL Lin*. miR-302 attenuates mutant huntingtin-induced cytotoxicity through restoration of autophagy and insulin sensitivity. Int J Mol Sci 22(16): 8424, 28th Aug. 2021. (SCI) IF=5.924; Ranking: 68/297=22.89%
  7. Li HH, PJ Lin, WH Wang, LH Tseng, H Tung, WY Liu, CL Lin1, CH Liu, WC Liao, CS Hung, YJ Ho*. Treatment effects of the combination of ceftriaxone and valproic acid on neuronal and behavioral functions in an epilepsy rat model. Experimental Physiology 106(8):1814-1828, 1st Aug 2021. (SCI) IF=2.969; Ranking: 38/81= 46.9%
  8. 洪菁穗，陳安芝，董欣，王瑋翰，何應瑞*。調節麩胺酸轉運蛋白於治療癲癇及其認知缺陷的可能效果:以頭孢曲松為例。台北市醫誌 pp.1-11, 2021。 (國內非SCI)
  9. Liu CH, BR Wu, YJ Ho, YH Chu, WC Hsu, TJ Tseng, JP Li, WC Liao*. CHPF regulates the aggressive phenotypes of hepatocellular carcinoma cells via the modulation of the decorin and TGF-β pathways. Cancers 13: 1261, 15, Mar. 2021. (SCI). IF=6.639; Ranking: 26/243=10.6%
  10. 洪菁穗、王瑋翰、董欣、戴春暉*、何應瑞*。治療癲癇的另類思維：併用克拉維酸與丙戊酸。臨床醫學 88(1): 463-468, Jul 13, 2021。 (國內非SCI)
  11. Liu,CH, YC Kuo, CY Wang, CC Hsu, YJ Ho, YC Chiang, FD Mai, WJ Lin, WC Liao*. Syndecan-3 contributes to the regulation of the microenvironment at the node of Ranvier following end-to-side neurorrhaphy: sodium image analysis. Histochem Cell Biol Oct. 10, 2020. (SCI); IF=4.302; Ranking: 1/9= 11%
  12. Chang CC, HH Li, SH Tsou, HC Hung, GY Liu, TJ Lai, TA Korolenko, YJ Ho*, CL Lin*. The pluripotency factor Nanog 6protects against neuronal amyloid β-induced toxicity and o7xidative stress through insulin sensitivity restoration. Cells 9(6), 13839, 2020. (SCI) IF=606; Ranking=51/195= 26.15%
  13. Cheng SM, YJ Ho, SH Yu, YF Liu, YY Lin, CY Huang, HC Ou, HL Hung, SD Lee. Anti-apototic effects of diosgenin in D-galactose-indiced aging brain. Am J Chin Med 48(2): 1-6, 2020. (SCI) IF=4.667; Ranking: 35/169=20.7%
  14. Liao WC, CK Liao, TJ Tseng, YJ Ho, YR Chen, KH Lin, TJ Lai, CT Lan, KC Wei, CH Liu. Chondroitin sulfate synthase 1 enhances proliferation of glioblastoma by modulating PDGFRA stability. Oncogenesis 9: 9, 2020. (SCI) IF=7.485; Ranking: 39/243=16%
  15. Liu CH, HM Chang, YS Yang, YT Lin, YJ Ho, TJ Tseng, CT Lan, ST Li, WC Liao. Melatonin promotes nerve regeneration following end to side neurorrhaphy by accelerating cytoskeletal remodeling via the melatonin receptor-dependent pathway. Neurosci 429: 282-92, 2020. (E-date 2019/11/07) (SCI) IF=3.59; Ranking: 141/273=51.6%
  16. Ho YJ* MS Shen, CH Tai, HH Li, JH Chen WC Liao, PY Chiu, IY Lee, CL Lin, CS Hung. Use of ceftriaxone in treating cognitive and neuronal deficits associated with dementia with Lewy bodies. Frontiers in Neuroscience 13: 507, Jun. 2019. DOI: 10.3389/fnins.2019.00507. (SCI) IF=4.667; Ranking: 88/273= 32.23%
  17. Volgin AD, A Bashirzade, TG Amstislavskaya, OA Yakovlev, KA Demin, YJ Ho, D Wang, VA Shevyrin, D Yan, Z Tang, J Wang, M Wang, ET Alpyshov, N Serikuly, EA Wappler-Guzzetta, AM Lakstygal, AV Kalueff. Dark classics in chemical Neuroscience: arecoline. ACS Chem Neurosci, 10(5): 2176-85, Jan. 2019. (SCI) IF=4.418; Ranking: 18/63=28.57%
  18. Lai CL, WM Chi, YJ Ho, CC Lin, HC Lin, CL Kuo, JH Chen* Using a Numerical Method to Precisely Evaluate the Alpha Angle in a Hip Image. Med Biol Eng Comput, published online: 08 April, 2019. (SCI) IF=2.602; Ranking: 22/58=47.9%
  19. Tai CH, M Bellesi, AC Chen, CL Lin, HH Li, PJ Lin, WC Liao, CS Hung*, RK Schwarting*, YJ Ho*. A new avenue for treating neuronal diseases: ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects. Behav Brain Res 364: 149- 156, Feb. 20, 2019. (SCI) IF=3.332; Ranking: 17/53=30.07%
  20. 何應瑞*、許弘毅、張鳴宏、廖玟潔、林志立*、洪菁穗*。從路易氏體失智症之病理特徵找尋治療方法 (Exploring a therapeutic method for dementia with Lewy bodies based on the pathophysiology)。台灣醫學雜誌 23(3): 376-83, 2019 (國內非SCI)
  21. 何應瑞*、沈枚萱、陳安芝、戴春暉、洪菁穗*、邱百誼*、賴德仁*。路易氏體失智症複雜的神經病理:頭孢曲松治療之潛力(Complicated pathophysiology of dementia with Lewy bodies: Therapeutic potential of ceftriaxone. Clinical Medicine 83(3): 185-93, 2019)。臨床醫學雜誌 83(3): 185-93, 2019 (國內非SCI)
  22. Kung WM, Ho YJ, H Yoshizawa, S Matsuo, CY Wei. Behavioural and cognitive changes in Lewy body dementia. Behavioural Neurology, vol. 2018, 2018. Article ID: 2404191, 2018. (SCI)
  23. Chang CC, TC Lin, HL Ho, HH Li, CY Kuo, TA Korolenko, WJ Chen, TJ Lai, YJ Ho*, CL Lin*. GLP-1 analogue Liraglutide attenuates mutant huntingtin-induced neurotoxicity by restoration of neuronal insulin signaling. Int J Mol Sci 19: 2505, 2018. (SCI)
  24. Ho YJ*, JC Weng, CL Lin, MS Shen, HH Li, WC Liao, NM Tsai, CS Hung*, TJ Lai*, IY Lee*. Ceftriaxone treatment for neuronal deficits: a histological and MEMRI study in a rat model of dementia with Lewy bodies. Behav Neurol 2018: 4618716, Aug. 2, 2018. (SCI)
  25. Chi WM,·CC Lin, YJ Ho, HC Lin, JH Chen*. Using nonlinear finite element models to analyse stress distribution during subluxation and torque required for dislocation of newly developed total hip structure after prosthetic impingement. Med Biol Eng Comput 56: 37- 47, 2018. (SCI)
  26. Chang CC, HH Li, YT Chang, YJ Ho, LJ Hsieh, PY Chiu, YS Cheng, CL Lin, TJ Lai. Abeta exacerbates α-synuclein-induced neurotoxicity through impaired insulin signaling in α-synuclein-overexpressed human SK-N-MC neuronal cells. CNS Neuroscience & Therapeutics 24(1): 47-57, 2018. . DOI: 10.1111/cns.12772. Oct. 11, 2017. (SCI)
  27. Hsieh MH#, WY Meng#, WC Liao#, JC Weng, HH Li, HL Su, CL Lin*, CS Hung*, YJ Ho*. Ceftriaxone reverses deficits of behavior and neurogenesis in an MPTP-induced rat model of Parkinson’s disease dementia. Brain Res Bull 132: 129- 38, 2017. (SCI)
  28. Tikhonova MA, SC Ho, AA Akopyan, NG Kolosova, JC Weng, WY Meng, CL Lin, TG Amstislavskaya, YJ Ho*. Neuroprotective effects of ceftriaxone treatment on cognitive and neuronal deficits in a rat model of accelerated senescence. Behav Brain Res, 330: 8-16, May. 12, 2017. (SCI)
  29. Chen LY, TY Renn, WC Liao, FD Mai, YJ Ho, G Hsiao, AW Lee, HM Chang. Melatonin successfully rescues hippocampal bioenergetics and improves cognitive function following drug intoxication by promoting Nrf2-ARE signaling activity. J Pineal Res e12417, May. 2, 2017. (SCI)
  30. Weng JC, MA Tikhonova, JH Chen, MS Shen, WY Meng, YT Chang, KH Chen, KC Liang, CS Hung, TG Amstislavskaya, YJ Ho*. Ceftriaxone prevents the neurodegeneration and decreased neurogenesis seen in a Parkinson’s disease rat model: an immunohistochemical and MRI study. Behav Brain Res 305: 126-39, Mar 08, 2016 (SCI)
  31. Lin CL, YS Cheng, HH Li, PY Chiu, YT Chang, YJ Ho, TJ Lai. Amyloid-β suppresses AMP-activated protein kinase (AMPK) signaling 2 and contributes to α-synuclein-induced cytotoxicity. Exp Neurol 275: 84-98, 2016. (SCI)
  32. Chi WM, CY Wang, LY Chen, YJ Ho, PJ Wu, JH Chen. Effects of Yuan Ji dance on standing balance control in community-dwelling middle-aged and elderly people. J Nan Kai, 12: 1, 21-30, 2015.
  33. Huang CK, YT Chang, TG Amstislavskaya, MA Tikhonova, CL Lin, CS Hung, TJ Lai, YJ Ho*. Synergistic effects of ceftriaxone and erythropoietin on neuronal and behavioral deficits in an MPTP-induced animal model of Parkinson’s disease dementia. Behav Brain Res 294: 198-207, Aug 15, 2015. (SCI)
  34. Tikhonova MA, AV Romaschenko, AE Akulov, YJ Ho, NG Kolosova, MP Moshkinb, TG Amstislavskaya. Comparative study of perception and processing of socially or sexually significant odor information in male rats with normal or accelerated senescence using fMRI. Behav Brain Res. 294: 89-94, Aug. 12, 2015. (SCI)
  35. Lin HC HC, WM Chi, YJ Ho, CC Lin, JH Chen. Theoretical Analysis of Total Hip Dislocation and Comparison of the Hemispherical Cup and a Newly Developed Cup. Med Biol Eng Comput 51(4): 397- 404, Apr. 1, 2015. (SCI, EI)
  36. Tikhonova MA, CH Ting, NG Kolosova, CY Hsu, JH Chen, CW Huang, GT Tseng, CS Hung, PFu Kao, TG Amstislavskaya, YJ Ho*. Improving bone microarchitecture in aging with diosgenin treatment: a study in senescence-accelerated OXYS rats. Chin J Physiol 58(5): 322-31, Oct. 31, 2015 (SCI)
  37. Hsu CY, CS Hung , HM Chang, WC Liao, SC Ho, YJ Ho*. Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson’s disease dementia. Neuropharmacol 91:43-56, 2015. (SCI)
  38. Chu SC, PN Chen, YJ Ho, CH Yu, YS Hsieh, DY Kuo*. Both neuropeptide Y knockdown and Y1 receptor inhibition modulate CART-mediated appetite control. Hormones and Behavior 67: 38-47, 2015. (SCI)
  39. Lin WL, SM Wang, YJ Ho, HC Kuo, YJ Lee, TH Tsen. Ethyl acetate extract of Wedelia chinensis inhibits tert-butyl hydroperoxide-induced damage in PC12 cells and D-galactose-induced neuronal cell loss in mice. BMC Complement Altern Med 14: 491, 2014. (SCI)
  40. Ho SC, CC Hsu, CR Pawlak, MA Tikhonova, TJ Lai, TG Amstislavskaya, YJ Ho*. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson’s disease rat model. Behav Brain Res 268: 177-84, May 05, 2014. (SCI)
  41. Ho SC, CC Hsu, CH Yu, WN Huang, MA Tikhonova, MC Ho, CS Hung, TG Amstislavskaya, YJ Ho*. Measuring Attention in a Parkinson’s disease Rat Model using the 5-arm Maze Test. Physiology & Behavior 130: 176-81, May 05, 2014. (SCI)
  42. Tikhonova MA, CH Yu, NG Kolosova, LA Gerlinskaya, SO Maslennikova, AV Yudina, TG Amstislavskaya, YJ Ho*. Comparison of behavioral and biochemical deficits in rats with hereditary defined or D-galactose-induced accelerated senescence: Evaluating the protective effects of diosgenin. Pharmacol Biochem and Behav 120: 7-16, Feb. 1, 2014. (SCI)
  43. Hung YT, MA Tikhonova, SJ Ding, PF Kao, HHC Lan, JM Liao, JH Chen, TG Amstislavskaya, and YJ Ho*. Effects of chronic treatment with diosgenin on bone loss in a D-galactose-induced aging rat model. Chin J Physiol 57(3): 121- 27, 2014. (SCI).
  44. Lin HC, WM Chi, YJ Ho, JH Chen. Effects of design parameters of total hip components on the impingement angle and determination of the preferred liner skirt shape with an adequate oscillation angle. Med Biol Eng Comput 51(4): 397- 404, Apr. 1, 2013. (SCI)
  45. Yang LH, YJ Ho, JF Lin, CW Yeh, SH Kao, LiS Hsu. Butein inhibits the proliferation of breast cancer cells through generation of reactive oxygen species and modulation of ERK and p38 activities. Molecular medicine reports 6(5):1126-32, Nov. 2012. (SCI)
  46. Hsia CH, CH Wang, YW Kuo, YJ Ho, HL Chen. Fructo-oligosaccharide systemically diminished D-galactose-induced oxidative molecule damages in BALB/cJ mice. British Journal of Nutrition 107: 1787–92, 2012. (SCI).
  47. Lin HC, WM Chi, YJ Ho, JH Chen*. Effects of design parameters of total hip components on the impingement angle and determination of the preferred liner skirt shape with an adequate oscillation angle. Med Biol Eng Comput 51(4): 397- 404, Apr. 1, 2013. (SCI).
  48. Hsia CH, CH Wang, YW Kuo, YJ Ho, HL Chen. Fructo-oligosaccharide systemically diminished D-galactose-induced oxidative molecule damages in BALB/cJ mice. British Journal of Nutrition 107: 1787–92, 2012. (SCI).
  49. Hsieh MH, SC Ho, KY Yeh, CR Pawlak, HM Chang, YJ Ho*, TJ Lai*, FY Wu. Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson’s disease rat model. Pharmacology, Biochemistry and Behavior 102: 64-71, 2012. (SCI).
  50. Pawlak CR, FS Chen, FY Wu, YJ Ho*. Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson’s disease and studies that need to be performed before clinical trials. Kaohsiung J Med Sci 28(8): 407-17, Aug. 16, 2012. (SCI).
  51. Ho YJ*, FL Chen, SM Liu, AL Wang, YC Li, TJ Lai, SS Huang. Effects of chronic resistive airway loading on behavioral changes in rats. Chin J Physiol 55(4): 245-252, Aug. 31, 2012. DOI: 10.4077/CJP.2012.BAA044 (SCI).
  52. Ho YJ*, SY Tai, CR Pawlak, AL Wang, CW Cheng, MH Hsieh. Behavioral and IL-2 Responses to Diosgenin in Ovariectomized Rats. Chin J Physiol 55(2): 91-100, 12 Apr, 2012. (SCI).
  53. Pawlak CR, BD Karrenbauer, P Schneider, YJ Ho. The elevated plus-maze test: differential psychopharmacology of anxiety-elated behavior. Emotion Review 4(1):98-115, Jan. 24, 2012. (SCI)
  54. Hsieh MH, SL Gu, SC Ho, CR Pawlak, CL Lin, YJ Ho*, TJ Lai, FY Wu. Effects of MK-801 on recognition and neurodegeneration in MPTP-induced Parkinson’s rat model. Behav Brain Res 229(1): 41-47, Jan. 10, 2012 (SCI)
  55. Schneider P, WF Wolfgang, N Schweinfurth, YJ Ho, A Sartorius, R Spanagel, CR Pawlak. Central metabolite changes and activation of microglia after peripheral interleukin-2 challenge. Brain Behav Immun, 26(2): 277-83, Feb. 1, 2012. (SCI)
  56. Chang CC, TC Kuan, YY Hsieh, YJ Ho, YL Sun, CS Lin. Effects of diosgenin on myometrial matrix metalloproteinase-2 and -9 activity and expression in ovariectomized rats. Int J Biol Sci 7: 837-847, July. 7. 2011. (SCI)
  57. Schneider P, YJ Ho, R Spanagel, CR Pawlak. A novel elevated plus-maze procedure to avoid the one-trial tolerance problem. Frontiers in Behavioral Neuroscience 5(43):1-8, July 27, 2011. (SCI)
  58. Ho YJ*, SC Ho, CR Pawlak, KY Yeh. Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson’s disease dementia. Behavioural Brain Research 219(2): 280-90, 2011. (SCI)
  59. Huang GJ, SC Ho, CK Lai, SL Gu, MH Hsieh, YJ Ho*. D-cycloserine reverses recognition deficits in MPTP-induced Parkinson’s disease mice model. Proceedings of XVII International Congress of Neuropathology, pp 31-35, 2010. (September 11-15, 2010, Salzburg, Austria)
  60. Ho SC, GJ Huang, CK Lai, SL Gu, MH Hsieh, Ho YJ*. MPTP-induced animal model of Parkinson’s disease dementia: there are species differences. Proceedings of XVII International Congress of Neuropathology pp 23-29, 2010. (September 11-15, 2010, Salzburg, Austria)
  61. Sy HN, SL Wu, WF Wang, CH Chen, YT Huang, YM Liou, CS Chiou, CR Pawlak, YJ Ho*. MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus. Pharmacol Biochem and Behav 95:158-165, Feb. 26, 2010. (SCI).
  62. Wang AL, YM Liou, CR Pawlak, YJ Ho*. Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats. Behav Brain Res 208: 38-46, Mar. 17th, 2010. (SCI).
  63. Wang WF, SL Wu, YM Liou, AL Wang, CR Pawlak, YJ Ho*. MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. Behavioral Neuroscience 123(6): 1261-70, Dec. 17th, 2009. (SCI).
  64. Karrenbauer BD, YJ Ho, V Ludwig, J Löhn, R Spanagel, RKW Schwarting, CR Pawlak. Time-dependent effects of striatal interleukin-2 on open field behaviour in rats. Journal of Neuroimmunology 208: 10-18, Mar. 31, 2009. (SCI).
  65. Bauhofer A, YJ Ho, A Schmitt, M Köster, RKW Schwarting, CR Pawlak. Individual behavioral differences in recovery from abdominal sepsis in rats. Inflammation Research 58:1-9, Feb. 5, 2009. (SCI).
  66. Lee SD, WW Kuo, YJ Ho, AC Lin, CH Tsai, HF Wang, CH Kuo, AL Yang, CY Huang, JM Hwang. Cardiac Fas-dependent and mitochondrial dependent apoptosis in ovariectomized rats. Maturitas 61:268-77, Nov. 20, 2008. (SCI).
  67. Chiang CY, KY Yeh, SF Lin, H Hsuchou, MY Tai, YJ Ho*, YF Tsai. Effects of alcohol on the mouse-killing behavior of olfactory bulbectomized rats. Chinese Journal of Physiology 51(6): 408-13, Dec. 31, 2008. (SCI)
  68. Chen JH, JSS Wu, HC Lin, SL Wu , WF Wang, SK Huang, YJ Ho*. Dioscorea improves the morphometric and mechanical properties of bone in ovariectomized rats. Journal of the Science of Food and Agriculture 88: 2700-06, Oct. 7. 2008. (SCI)
  69. Pawlak CR*, YJ Ho*, R. K.W. Schwarting*. Animal models of human psychopathology based on individual differences in novelty-seeking and anxiety. Neuroscience & Biobehavioral Reviews 32: 1544-68, Oct. 10. 2008. (SCI)
  70. Lee YT, WF Wang, CW Cheng, SL Wu, CR Pawlak, YJ Ho*. Effects of escapable and inescapable stressors on behavior and interleukin-2 in the brain. Neuroreport 19(12): 1243-47, Aug. 6. 2008. (SCI)
  71. Hsieh YS, SF Yang, SC Chu, YJ Ho, CS Kuo, DY Kuo. Transcriptional interruption of cAMP response element binding protein modulates superoxide dismutase and neuropeptide Y-mediated feeding behavior in freely moving rats. Journal of Neurochemistry 105: 1438-1449, May. 2008. (SCI)
  72. Wu SL, LS Hsu, WT Tu, WF Wang, YT Huang, CR Pawlak*, YJ Ho*. Effects of D-cycloserine on the behavior and ERK activity in the amygdala: Role of individual anxiety levels. Behavioral Brain Research 187(2): 246-53, Mar. 5. 2008. (SCI)
  73. Ho YJ*, WY Hsu, CF Wang, T Tseng, CW Cheng, YC Hung, CC Hsu, MD Kao, YF Tsai. Psychoimmunological effects of dioscorea in the ovariectomized rats: role of anxiety level. Annals of General Psychiatry 6:21, Aug. 10, 2007.
  74. Wang WF, YP Lei, T Tseng, WY Hsu, CF Wang, CC Hsu, YJ Ho*. Effects of apomorphine on the expression of learned helplessness behavior. Chinese Journal of Physiology 50(2): 63-68, Apr. 30, 2007. (SCI).
  75. Chen LM, WW Kuo, JJ Yang, SG Wang, YL Yeh, FJ Tsai, YJ Ho, MH Chang, CY Huang, SD Lee. Eccentric cardiac hypertrophy was induced by long-term intermittent hypoxia. Experimental Physiology 92(2):409-16 Mar. 2007. (SCI).
  76. Ho YJ*, LS Hsu, CF Wang, WY Hsu, TJ Lai, CC Hsu, YF Tsai. Behavioral effects of D-cycloserine in rats: the role of anxiety level. Brain Res 1043: 179-185, May. 2005. (SCI).
  77. Ho YJ, KH Chen, MY Tai, YF Tsai. MK-801 suppresses muricidal behavior but not locomotion in olfactory bulbectomized rats: involvement of NMDA receptors. Pharmacol Biochem Behav 77: 641-46, Mar. 2004. (SCI).
  78. Ho YJ, H Hsuchou, HA Shui, MY Tai, KH Chen, YF Tsai. Effects of desipramine and MK-801 on components of muricidal behavior in olfactory bulbectomized rats: an application of incisor-cutting animal model. Neurosci Res Comm 34(3): 136-43, May. 2004. (SCI).
  79. Ho YJ, CR Pawlak, LH Ku, RKW Schwarting. Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat. Behav Brain Res 149: 135-44, Mar. 2004. (SCI).
  80. Pawlak CR, YJ Ho, RKW Schwarting, A Bauhofer. Relationship between striatal levels of interleukin-2 mRNA and plus-maze behaviour in the rat. Neurosci Lett 341: 205-08, May. 2003. (SCI).
  81. Ho YJ, J Eichendorff, RKW Schwarting. Individual response profiles of male Wistar rats in animal models of anxiety and depression. Behav Brain Res 136: 1-12, Oct. 2002. (SCI).
  82. Hsuchou H, YJ Ho, HA Shui, MY Tai, KH Chen, YF Tsai. Effects of incisor cutting on muricidal behavior induced by olfactory bulbectomy in rats. Physiol and Behav 76 (4-5): 669-75, Aug. 2002. (SCI).
  83. Ho YJ, TM Liu, MY Tai, CS Wong, YF Tsai. Effects of olfactory bulbectomy on the density of NMDA receptors in rat’s brain: [3H] MK-801 binding assay. Brain Res 900: 214-18, May. 11, 2001. (SCI)
  84. Ho YJ, YC Chang, TM Liu, MY Tai, CS Wong, YF Tsai. Striatal glutamate release during novelty exposure-induced hyperactivity in olfactory bulbectomized rats. Neurosci Lett 287 (2): 117-20, Jun. 23, 2000. (SCI)
(B) In Chinese with English Abstract
  1. 何應瑞*、沈枚萱、陳安芝、戴春暉、洪菁穗*、邱百誼*、賴德仁*。路易氏體失智症複雜的神經病理:頭孢曲松治療之潛力(Complicated Pathophysiology of Dementia with Lewy Bodies: Therapeutic Potential of Ceftriaxone)。臨床醫學雜誌 83(3): 185-93, 2019
  2. 何應瑞*、許弘毅、張鳴宏、廖玟潔、林志立*、洪菁穗*。從路易氏體失智症之病理特徵找尋治療方法( Exploring a Therapeutic Method for Dementia with Lewy Bodies based on the Pathophysiology)。台灣醫學雜誌 23(3): 376-83, 2019
  3. 何應瑞*、許兆畬、陳福士、洪菁穗、賴德仁。紅血球生成素之神經保護效果：應用於治療巴金森氏症失智為例。澄清醫護管理雜誌11(3): 37-42, Jul, 2015. (Neuronal protection of erythropoietin: a possible application in Parkinson’s disease dementia. Cheng Ching Medical Journal 11(3): 37-42, Jul, 2015)
  4. 廖丹瑜、洪櫻慈、周璟言、黃冠達、何詩君、黃國洲、張思毅、徐詩惠、吳聲輝、廖娟妙＊、何應瑞* 。增加麩胺酸轉運子之表現對巴金森氏症大鼠的認知缺陷之效果。中華民國生醫材料及藥物致放學會2012年會論文集，Apr., 2012, Taipei。【Liao TY, YT Hung, CY Chou, GD Huang, SH Ho, GJ Huang, SY Chang, SH Hsu, SH Wu, JM Liao, YJ Ho*. Effects of enhancing glutamate transporter expression on cognitive dysfunction in Parkinson’s disease rat model. Biomaterials and Drug Delivery Systems 2012 Annual Meeting and Symposium, Apr., 2012, Taipei.】
  5. 陳福士、黃國洲、吳富英、何應瑞*。Amantadine抑制巴金森氏症失智及NMDA受體於其中所扮演之角色：文獻回顧與探討。臨床醫學 68(5): 386-92, Nov. 1, 2011。
  6. 莊婷、謝明鴻、陳福士、吳富英、何應瑞*。D-cycloserine加強暴露療法治療恐懼症之文獻回顧。台灣醫學 15(6): 1-11, Jun 21, 2011. 。【Chuang T, MH Hsieh, FS Chen, FY Wu, YJ Ho*. D-cycloserine facilitates the effects of exposure therapy on phobias. Formosan J Medicine 15(6): 1-11, Jun 21, 2011. (in Chinese with English abstract).】
  7. 何應瑞*、巫錫霖、王文甫、施曉雅、黃耀庭。巴金森氏症患者的幻覺及其可能的神經心理機轉。台灣醫學 14(1): 88-96, Jan. 1st, 2010。【YJ Ho*, Wu SY, Wang WF, Sy HN, Huang YT. Hallucinations in Parkinson’s disease: the possible neuropsychological mechanisms, Formosan J Medicine 14(1): 88-96, Jan. 1st, 2010. (in Chinese with English abstract).】
  8. 何應瑞*、巫錫霖、王文甫、黃耀庭、鄭鈞文。麩胺酸神經系統與神經免疫功能在巴金森氏症失智的可能角色。台灣醫學 13(1): 100-06, Jan. 1st. 2009。(CCH grant 93118 and 92521; NSC 96-2320-B-040-019) 【Ying-Jui Ho*, Shey-Lin Wu, Wen-Fu Wang, Yao-Ting Huang, Chun-Wen Cheng. Role of glutamatergic and neuroimmunological function in the dementia in Parkinson’s disease. Formosan J Medicine 13(1): 100-06, Jan. 1st. 2009】
  9. 王慶福、游顯妹、王郁茗、何應瑞、曾淑梅。配合生理回饋之放鬆訓練對重症加護病房護理人員焦慮反應之影響效果【The effects of biofeedback-assisted relaxation on nursing staffs with anxiety reaction in ICU, Chung Shan Medical Journal】。中山醫學雜誌，18(2): 241-53, Dec. 2007。
  10. 王慶福、鍾麗珍、王郁茗、何應瑞、賴德仁。生理回饋訓練與放鬆訓練對大學生焦慮與憂鬱反應之影響效果 (Effect of biofeedback training and relaxation training on anxiety and depressive reactions of college students, Chung Shan Medical Journal）。中山醫學雜誌，18(2): 255-70, Dec. 2007。
  11. 黃秋谷、王慶福、徐文鈺、何應瑞*、黃耀庭、賴德仁。影響神經功能並參與情感疾病之發炎物質：心理神經免疫學之基礎。臨床醫學月刊58(1):51-56, Jul. 2006。【Huang CK, CF Wang, WY Hsu, YT Huang, TJ Lai, YJ Ho*. Inflammatory substances affecting neuronal function and affective disorders: fundamentals of psychoneuroimmunology. Clinical Medicine 58(1): 51-56, Jul. 2006. (in Chinese with English abstract)】
  12. 何應瑞*、蔡元奮。麩胺酸神經系統在憂鬱症中可能的角色：以嗅球被切除之大鼠為動物模式所得的證據。台灣精神醫學雜誌 19(1): 5-18, Mar. 2005. (TSSCI). 【YJ Ho*, YF Tsai. Possible Role of Glutamatergic System in Depression: Evidence from Animal Model of Olfactory Bulbectomized Rats. Taiwanese J Psych 19(1): 5-18, Mar. 2005.】
  13. 杜瑋庭、曾鼎、王安莉、鍾宛玲、林俊成、許立松、徐文鈺、王慶福、何應瑞*。NMDA受體在D-cycloserine對焦慮行為作用之角色。台灣醫學 9(2): 173-179, Mar. 2005.【Tu WT, T Tseng, AL Wang, WL Chung, CC Lin, LS Hsu, WY Hsu, CF Wang, YJ Ho. Effects of D-cycloserine on anxiety behavior: role of NMDA receptor. Formosan Journal of Medicine 9(2): 173-197, Mar. 2005.) (in Chinese with English abstract)】
  14. 黃秋谷、王慶福、徐文鈺、賴德仁、何應瑞*。麩胺酸神經系統NMDA受體在精神分裂症之角色：作用在甘胺酸結合位之藥物所得的證據。臨床醫學月刊 55(4): 253-258, Apr. 2005. 【Huang CK, CF Wang, WY Hsu, TJ Lai, YJ Ho*. Role of glutamatergic NMDA receptor in schizophrenia: evidence from drugs acting at the glycine binding site. Clinical Medicine 55(4): 253-258, Apr. 2005. (in Chinese with English abstract)】
  15. 黃秋谷、何應瑞*。搖頭丸：危險的急性中毒與棘手的慢性中毒。臨床藥學雜誌10 (2): 49-62, 2002. (Huang CK, YJ Ho*. “Ecstasy”, its dangerous acute-effects and long-term toxicity. Formosa J Clinic Pharmacy 10 (2): 49-62, 2002. (in Chinese with English abstract))
  16. 何應瑞*。山藥，植物性的賀爾蒙。常春月刊 164:90-93, 1996。 【Ho YJ. Dioscorea, Phytohormone. Evergreen 164:90-93, 1996. (in Chinese with English abstract)】
(C) Conference Abstract

More than 170 conference abstracts, since 1995.

(D) Patent
編號Inventor/ ApplicantTitleNationNo./Term
1何應瑞、陳建宏/亞瑟瑞智包含克拉維酸與丙戊酸之組合物及其用途<CA+Val癲癇>歐盟 
2何應瑞、陳建宏/亞瑟瑞智包含克拉維酸與丙戊酸之組合物及其用途<CA+Val癲癇>ChinaZL201911170003.9
3何應瑞、陳建宏/亞瑟瑞智包含克拉維酸與丙戊酸之組合物及其用途<CA+Val癲癇>TaiwanI739220
4Ho YJ/ 百朗克公司BrainX corporationUse of ceftriaxone to treat dementia with Lewy bodies <DLB>Canada3003860號 (2018.05.03- 2038.05.02)
5Ho YJ/ 百朗克公司BrainX corporationUse of ceftriaxone to treat dementia with Lewy bodies <DLB>Japan特許第6662949號 (2018.05.17- 2038.05.17)
6Ho YJ/ 百朗克公司頭孢曲松的用途: 治療路易氏體失智症<DLB>TaiwanI644673 (20181221- 20370726)
7發明人：何應瑞、陳建宏。申請人：中山醫大、江文舜包含紅血球生成素及頭孢曲松的巴金森氏症失智用組合物 <併用CEF+EPO PDD>Korea第10-1971318號 (2019.04.16- 2036.04.21)
8Ho YJ, Chen JH/ CSMU, Vincent ChinA Pharmaceutical Composition Comprising Erythropoietin and Ceftriaxone and A Use Thereof in the Manufacture of a Medicament for the Treatment of Parkinson’s Disease Dementia <併用CEF+EPO PDD>Europe (German, France, Great Britain, Poland, 10國)EP3085383 (20181128- 20360420) 波蘭: PL3085383T3 西班牙: ES2714123T3 土耳其: TR201902863T4 
9何應瑞、陳建宏/中山醫大、江文舜使用一包含有頭孢曲松與紅血球生成素的組合來治療和/或預防巴金森氏症失智 <併用CEF+EPO PDD>TaiwanI558410 (201611- 203504)
10Ho YJ, Chen JH/ CSMU, Vincent Chin使用頭孢曲松來治療和/或預防巴金森氏症失智(Treatment and / or prevention of Parkinson’s disease dementia with ceftriaxone)USAUS 9,326,988 B2 (20130313- 20330312?)
11何應瑞、陳建宏/中山醫大、江文舜用头孢曲松制备治疗和/或预防帕金森氏症失智的医药品的用途 Applications of medicine prepared from ceftriaxone and used for curing and/or preventing dementia caused by Parkinson’s disease <讓與百朗克200410>ChinaZL201210154964.2 (201205- 203205)
12Ho YJ, Chen JH/ CSMU, Vincent ChinA use of pharmaceutical composition comprising erythropoietin and ceftriaxone in the manufacture of a medicament for the treatment of Parkinson’s disease dementia <併用CEF+EPO PDD>AustraliaAU2016202491B2 104112897 (20160420- 20360419)
13Ho YJ, Chen JH/ CSMU, Vincent ChinA use of pharmaceutical composition comprising erythropoietin and ceftriaxone in the manufacture of a medicament for the treatment of Parkinson’s disease dementia <併用CEF+EPO PDD>Japan特許第6298490號 (20160420- 20360419)
14何應瑞 /何應瑞、中山醫大用於治療神經退化性疾病之醫藥組合物 (Pharmaceutical compositions for treatment of neurodegenerative disorders) <DCS PDD>TaiwanI544923 (201608- 202912)
15陳建宏、何應瑞 /中山醫學大學全人工髖關節結構(Total hip structure)TaiwanI546063 (201502- 203602)
16何應瑞、陳建宏 /中山醫學大學、何應瑞、晉亞化工廠使用薯蕷皂素來改善停經症候群有關聯的認知缺陷 申請人（更名前）：中山醫學大學、何應瑞、瑞金生物科技有限公司 申請人（更名後）：中山醫學大學、何應瑞、百朗克醫藥股份有限公司 (200326)  ChinaZL 201110100440.0 (201306- 203305)
17何應瑞、陳建宏 /中山醫學大學使用薯蕷皂素來改善與停經期症候群有關聯的認知缺陷（Improvement of cognitive deficit Associated with Menopausal syndrome with diosgene）TaiwanI422378 (201401- 203412)
18何應瑞 / 鴻剛實業股份有限公司動物注意力訓練及測量裝置 (Instrument for measuring and training animal attention)TaiwanM433088 (201206- 202202)
(E) Book
  1. 人體生理學：身體功能之機轉。賴義隆、何應瑞等譯自Vander, Sherman, Luciano’s Brief Edition Human Physiology。2006年，藝軒圖書出版社。（ISBN：986157252X）
  2. 王春美、何應瑞、施柯念、秦作威、高婷玉、溫小娟、葉睿毅、廖美華、滿庭芳、駱明潔、盧敏吉、顏惠芷。新編生理學。華格那企業有限公司，2004年，台中市。(ISBN 986-7905-27-X)

    Ho YJ. (2003). Nervous system. In CM Chung (Eds.): Current Physiology. Wagner Publishing Co. Ltd., Tai-Chung, Taiwan. 77-120. (ISBN 986-7905-27-X)

    Ho YJ. (2003). The central nervous system. In CM Chung (Eds.): Current Physiology. Wagner Publishing Co. Ltd., Tai-Chung, Taiwan. 121-148. (ISBN 986-7905-27-X)
  3. 吳莉玲、朱冠州、何應瑞。生理學精要。藝軒圖書出版社，2003年，台北市。(ISBN 9576167108)
  4. 吳莉玲、何應瑞。生理學精華。藝軒圖書出版社，2002年，台北市。(ISBN 9576166799)

TECHNALOGY TRANSLATION

項次技術名稱雙方性質日期
1運用ceftriaxone或clavulanic acid治療癲癇或以ceftriaxone合併valproic acid或以clavulanic acid 合併valproate 治療癲癇之技術中山醫大/亞瑟瑞智公司技術移轉2019.10.0550萬
2合併使用頭孢曲松與紅血球生成素於神經退化及認知障礙及頭孢曲松應用於治療抗老化之運東功能障礙及神經退化 (申請專利中)中山醫大/嘉詠授權實施 (中山之40%)2017.01.13 
3頭孢曲松應用在治療抗老化之運動功能障礙、認知功能障礙及神經退化合併使用頭孢曲松與紅血球生成素於神經退化及認知障礙中山醫大/江文舜合作申請專利 (40:60)2014.11.27 
41. 使用紅血球生成素於治療路易氏體失智症認知功能障礙及神經退化 2. 使用頭孢曲松於治療路易氏體失智症認知功能障礙及神經退化中山醫大/瑞金生物科技公司讓與2017.02.10100萬
5探討ceftriaxone治療巴金森氏症動物之神經退化與行為缺陷的效果 (何應瑞)中山醫大/晉亞化工合作申請專利2011.05.03 
PROFESSIONAL MEMBERSHIPS
  • Japanese Neuroscience Association
  • Taiwan Neuromodulation Society
  • Taiwanese Psychological Association
  • Society for Neuroscience
  • The Chinese Physiological Society
  • The Chinese Neuroscience Society
LICENCE
  • 專門職業及技術人員高等考試藥師藥字第17091號 (Pharmacist of ROC)
  • AI與Big Data驅動智慧財產營運新模式 (磐安MMOT2021)
  • 生技醫藥專利人員培訓 (光鹽2021)
  • 新藥委外開發成功關鍵金三角評估、管理與策略規劃  (生技產業深耕學院2020)
  • 專利檢索與資訊分析 (智合創新顧問有限公司2020)
  • 遴選臨床試驗優良供應商 (光鹽2020)
  • 國際技術移轉經理人培訓 (英國牛津大學OXENTIA2020)
  • 2020國際技術移轉培訓 (資策會2020)
  • 創業股權規劃與技術作價 (財團法人生技中心2020)
  • 製藥工程師培訓:藥廠法規人員實務 (光鹽學苑2019)
  • 跨領域科技管理研習班  (磐安MMOT2019)
  • 大健康人才培訓班 (2019)
  • 精準醫療神經疾病分子檢測 (2019)
  • 科技與智慧財產最新發展因應策略 (MMOT2019)
HONOR AND AWARDS
  • 2016 Special Talents Award (MOST, ROC. 2016.08.01- 2022)
  • 2015 Special Talents Award (MOST, ROC. 2015.08.01- 2016.07.31)
  • 2014 Special Talents Award (MOST, ROC. 2014.08.01- 2015.07.31)
  • 2014 Super Teacher Award (Teachers Union of Taichung, ROC. 2015)   
  • 2013 Outstanding Teaching Award, Chung Shan Medical University
  • 2013 Special Talents Award, National Science Consul (NSC, ROC. 2013.08.01- 2014.07.31) 
  • 2012 Special Talents Award, National Science Consul (NSC, ROC. 2012.08.01- 2013.07.31)
  • 2005 Aristotle Research Award, The International Society on Brain and Behaviour, Europ
  • 2003 Award of Outstanding Scientific Achievement and Presentation, Neuroscience Society, ROC
  • 2001 Visiting Scholar of NSC and DAAD, Germany 
  • 2000 Award of Scholarship from Chung Hwa Rotary Educational Foundation, ROC  1993 Award of Scholarship from Academic Research Foundation, ROC
UNIVERSITY COMMITTEES
  • Interviewer, Department of Psychology applicants, Chung Shan Medical University (2002-present)
  • Committee on Faculty Promotions and Evaluation, School of Psychology, Chung Shan Medical University (2002-present)
  • Committee on Faculty Promotions and Evaluation, School of Optometry, Chung Shan Medical University (2002-present)
  • Committees, Environment and Safety Office, Chung Shan Medical University (2002-present)